Innovative Health Initiative (IHI)
Important Disclaimer:
The purpose of this document is to present the status of discussions between 5 health industry associations. The content should not be considered as final or pre-emptive of final legislative decision about future public private partnerships under Horizon Europe.
IHI at a glance

• Joint Undertaking (based on Article 187 TFEU) between the European Commission and the healthcare industry

• Cross sectorial between
  • pharmaceutical sector (EFPIA, Vaccines Europe, EuropaBio)
  • medical technologies sector (MedTech Europe, COCIR)

• Budget over 7 years
  • €1.2 billion funding from the European Union (Horizon Europe)
  • €1.2 billion in kind from industry and contributing partners

• Legislative process ongoing
  Commission’s Proposal for a Council Regulation establishing the Joint Undertakings under Horizon Europe
Moving to new EU/Industry partnerships in healthcare, in a changing world

**Need for change**
- Siloed industries
- Different sets of standards
- Translation of science
- Reimbursement focus
- Locked value of data analytics

**Rapid advances**
- Scientific and tech advancements
- Digital therapies appearing
- Precision therapies and personalised medicines emerging
- Big data as a critical enabler

**New cross-sector PPP**
- Diagnostics and biotech to bring new capabilities and standards
- Cross-sector activities will aim to remove siloed activity
- Support translation of scientific with tech advances and big data to improve health
A paradigm shift for Innovation in Healthcare

From disease care ... 
...to health care and learning healthcare systems 
with the citizen/patient at the centre
Objectives

1. Better understand the determinants of health and priority disease areas
2. Integrate fragmented health research and innovation efforts
3. Demonstrate the feasibility of people-centred, integrated health care solutions
4. Exploit the full potential of digitalisation and data exchange in health care
5. Develop new and improved methodologies and models for the assessment of the added value of innovative and integrated health care solutions.
Strategic Research & Innovation Agenda

- Better understanding of the determinants of health and priority disease areas
- Integration of fragmented health care Research & Innovation efforts
- Development of people-centred, integrated health care solutions
- Full use of digitalisation and data exchange in health care
- Assessment of the added value of innovative and integrated health care solutions

Benefits for European citizens, healthcare systems & industry
### From IMI to IHI

<table>
<thead>
<tr>
<th><strong>1. PRIVATE TRADE ASSOCIATIONS</strong></th>
<th><strong>Current IMI</strong></th>
<th><strong>New IHI</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1x trade association</td>
<td>5x trade associations</td>
</tr>
<tr>
<td></td>
<td>• EFPIA (incl. Vaccines Europe)</td>
<td>• EFPIA, COCIR, MedTech Europe, Vaccines Europe</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>2. CONSORTIUM FORMATION</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-stage call; public partners &amp; SMEs selected by independent experts to join private partner consortium</td>
<td>Two stage call continues One stage call added; public and private partners form consortium</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>3. STRATEGIC FOCUS</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Guided by SRA with input from Strategic Governing Groups based around therapeutic areas [TA].</td>
<td>Guided primarily by SRIA and the 5 Focus Areas / Specific Objectives, with input from Focus Groups and the Innovation Panel.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>4. FUNDING MODEL</strong></th>
<th><strong>Current IMI</strong></th>
<th><strong>New IHI</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>50% European Commission 50% EFPIA</td>
<td>50% European Commission 25% EFPIA, EuropaBio, Vaccines Europe 25% MedTech Europe + COCIR</td>
</tr>
</tbody>
</table>
Participants to projects

• The Innovation Panel represents the stakeholders to explore, identify and/or review potential areas and topics, suitable for the scope of the PPP

• Public partners + SMEs funded 100%
2 types of calls

1-stage
• Broad topic, not specific to one single product/technology/solution
• Private Members apply simultaneously with Public Members in mixed consortia
• Due to its nature of openness and competitive character, Private Members can receive funding
• Pharma companies will abstain from requesting funding

2-stage
• Targeted topics and budget are determined by Private Members
• Anyone interested can subscribe to these calls, in line with available funding
• Winning consortium is coupled to Private Members’ consortium to prepare second stage full proposal
• Due to its nature of company-detailed topics, Private Members are not eligible for funding
• In fact, no funding will be made available for any company with annual turnover > 500M
Opening up the process for idea generation

• Early engagement with public sector stakeholders for the definition of priorities: co-design of the annual priorities with the Innovation Panel
  - involving all relevant public and private stakeholders from the health care ecosystem
  - explore, identify and/or review potential areas and topics, suitable for the scope of the PPP, and which would secure in-kind commitment from industry

• Member States: States Representatives Group
  - consulted on the call topic ideas and texts
  - provides advice on potential complementarities and overlaps with relevant national initiatives
Synergies with other initiatives

• European Partnership for EU-Africa Global Health
• European Partnership for Chemicals Risk Assessment
• European Partnership - ERA for Health Research
• European Partnership on Health and Care Systems Transformation
• European Partnership for Personalised Medicine
• European Partnership on Rare Diseases
• European Partnership for One Health/AMR Antimicrobial Resistance (AMR)

• Health Cluster
• Mission on Cancer
Timeline (tentative)

- **Strategic Research & Innovation Agenda**
  - June: Draft SRIA publication
  - Autumn: Draft Annual Work Programme
  - Q4 2021: Adoption of the SRIA & AWP

- **Legislative Process**
  - 2021: First PPP Call
  - 2022: 1st call campaign
  - End-2021: First PPP Call
  - Q4 2021: Adoption of the Single Basic Act
More information

• Inter-association website: [www.EUHealthPPP.org](http://www.EUHealthPPP.org), including
  • Draft SRIA
  • Case studies

• European Commission: [Candidates for European Partnerships in health](https://ec.europa.eu)

• IMI website: [Innovative Health Initiative page](https://www.imi.europa.eu)

• Contact us: [contact@euhealthppp.org](mailto:contact@euhealthppp.org)
Background
# IHI Trade Organisations At-a-Glance

<table>
<thead>
<tr>
<th>Trade Association</th>
<th>Represents</th>
<th>Mission/Vision</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EFPIA</strong></td>
<td>Pharmaceutical industry</td>
<td>To create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.</td>
</tr>
<tr>
<td><strong>COCIR</strong></td>
<td>Medical imaging, radiotherapy, health ICT and electromedical industries</td>
<td>Our industry provides safe and high quality products and services, which contribute to reducing health inequalities and enhance cost efficiency in healthcare systems. COCIR's key objective is to promote free worldwide trade of innovative medical technology while maintaining the competitiveness of the European medical imaging, radiotherapy, electromedical and health ICT industries.</td>
</tr>
<tr>
<td><strong>MedTech Europe</strong></td>
<td>Medical Technology industry</td>
<td>Make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.</td>
</tr>
<tr>
<td><strong>Vaccines Europe</strong></td>
<td>Vaccine industry</td>
<td>To support broad access to immunisation, enabling better protection of the health of individuals and the wider community throughout life, with both existing vaccines and those in development.</td>
</tr>
<tr>
<td><strong>EuropaBio</strong></td>
<td>Biotech industry</td>
<td>Committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy.</td>
</tr>
</tbody>
</table>